Amneal Announces FDA Approval For Spironolactone HCl Tablets
Main Category: Urology / NephrologyAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 29 Aug 2010 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010. The Amneal generic is an AB-rated, therapeutically equivalent alternative to Aldactone® (a registered trademark of Pharmacia & Upjohn, Inc., a unit of Pfizer Inc.). Annual U.S. sales of Spironolactone HCl were $91 MM as of December 2009 according to IMS Health market data.
Spironolactone HCl is a synthetic 17-lactone drug that is a renal competitive aldosterone antagonist in the class of pharmaceuticals known as potassium-sparing diuretics. It is indicated in the management of primary hyperaldosteronism, edematous conditions (for patients with congestive heart failure, cirrhosis of the liver accompanied by edema and/or ascites, the nephritic syndrome), essential hypertension, hypokalemia and severe heart failure (NYHA class III-IV).
Amneal began shipping Spironolactone HCl in 100- and 500-count sizes on July 21, 2010. The 25 mg strength can also be ordered in 1000-count size. This product is available through wholesalers-distributors as well as directly to the trade. The tablets are produced in the company's fully cGMP-compliant Hauppauge, NY facility. Amneal manufactures all of its own generics in the USA and continues to expand its U.S.-based production.
Spironolactone HCl is the most recent addition to Amneal's rapidly growing portfolio, listed in the company's on-line catalog of 250 products here. Launched one year ago, the comprehensive web catalog is designed for easy customer and patient access to essential information, images and literature such as product outserts, labels, patient medication guides, MSDS (material safety data sheets) and high-resolution product photos.
Source:
Amneal Pharmaceuticals, LLC
Visit our urology / nephrology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/199223.php>
APA
http://www.medicalnewstoday.com/releases/199223.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



